Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Truist Securities Reiterates Buy on Vertex Pharmaceuticals, Raises Price Target to $550

Author: Benzinga Newsdesk | August 05, 2024 10:19am
Truist Securities analyst Joon Lee reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $508 to $550.

Posted In: VRTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist